Hipra 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bimervax (PHH-1V) / Hipra
NCT05246137 / 2022-000074-25: A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

Completed
3
2646
Europe
COVID-19 Vaccine 40 ug/dose
Hipra Scientific, S.L.U
COVID-19, SARS-CoV-2 Acute Respiratory Disease
03/22
03/23
HIPRA-HH-4, NCT05303402 / 2022-000785-18: A Phase III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.

Completed
3
241
Europe, RoW
PHH1-V
Hipra Scientific, S.L.U, Veristat, Inc., Asphalion, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
SARS CoV 2 Infection
07/23
12/23
NCT05305573 / 2022-000795-19: Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.

Completed
2b
26
Europe
COVID-19 Vaccine HIPRA 40 ug/dose, Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
Hipra Scientific, S.L.U
COVID-19, SARS-CoV-2 Acute Respiratory Disease
10/22
10/22
NCT05142514: Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)

Completed
2
629
RoW
COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
Hipra Scientific, S.L.U, Laboratorios Hipra, S.A., National Institute of Hygiene and Epidemiology, Vietnam
COVID-19, SARS-CoV-2 Acute Respiratory Disease
12/21
05/22
HIPRA-HH-2, NCT05142553 / 2021-005226-26: Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

Completed
2
887
Europe
COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
Hipra Scientific, S.L.U, Laboratorios Hipra, S.A.
COVID-19, SARS-CoV-2 Acute Respiratory Disease
05/23
05/23
NCT06234956: Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.

Recruiting
2
300
Europe
BIMERVAX
Hipra Scientific, S.L.U, Veristat, Inc., VHIR, Asphalion
SARS CoV 2 Infection
12/24
12/24
NCT05981846: A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19

Completed
2
279
Europe
BIMERVAX, SIIV
Hipra Scientific, S.L.U
SARS CoV 2 Infection, Influenza, Human
10/23
11/23
HIPRA-HH-1, NCT05007509 / 2021-001411-82: Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)

Completed
1/2
30
Europe
COVID-19 vaccine HIPRA 10, COHORT 1, COVID-19 vaccine HIPRA 20, COHORT 2, COVID-19 vaccine HIPRA 40, COHORT 3, Commercial COVID-19 vaccine
Laboratorios Hipra, S.A.
Covid19, SARS CoV 2 Infection
09/21
09/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bimervax (PHH-1V) / Hipra
NCT05246137 / 2022-000074-25: A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

Completed
3
2646
Europe
COVID-19 Vaccine 40 ug/dose
Hipra Scientific, S.L.U
COVID-19, SARS-CoV-2 Acute Respiratory Disease
03/22
03/23
HIPRA-HH-4, NCT05303402 / 2022-000785-18: A Phase III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.

Completed
3
241
Europe, RoW
PHH1-V
Hipra Scientific, S.L.U, Veristat, Inc., Asphalion, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
SARS CoV 2 Infection
07/23
12/23
NCT05305573 / 2022-000795-19: Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.

Completed
2b
26
Europe
COVID-19 Vaccine HIPRA 40 ug/dose, Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
Hipra Scientific, S.L.U
COVID-19, SARS-CoV-2 Acute Respiratory Disease
10/22
10/22
NCT05142514: Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)

Completed
2
629
RoW
COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
Hipra Scientific, S.L.U, Laboratorios Hipra, S.A., National Institute of Hygiene and Epidemiology, Vietnam
COVID-19, SARS-CoV-2 Acute Respiratory Disease
12/21
05/22
HIPRA-HH-2, NCT05142553 / 2021-005226-26: Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

Completed
2
887
Europe
COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
Hipra Scientific, S.L.U, Laboratorios Hipra, S.A.
COVID-19, SARS-CoV-2 Acute Respiratory Disease
05/23
05/23
NCT06234956: Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.

Recruiting
2
300
Europe
BIMERVAX
Hipra Scientific, S.L.U, Veristat, Inc., VHIR, Asphalion
SARS CoV 2 Infection
12/24
12/24
NCT05981846: A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19

Completed
2
279
Europe
BIMERVAX, SIIV
Hipra Scientific, S.L.U
SARS CoV 2 Infection, Influenza, Human
10/23
11/23
HIPRA-HH-1, NCT05007509 / 2021-001411-82: Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)

Completed
1/2
30
Europe
COVID-19 vaccine HIPRA 10, COHORT 1, COVID-19 vaccine HIPRA 20, COHORT 2, COVID-19 vaccine HIPRA 40, COHORT 3, Commercial COVID-19 vaccine
Laboratorios Hipra, S.A.
Covid19, SARS CoV 2 Infection
09/21
09/22

Download Options